Gliosarcoma: a clinical and radiological analysis of 48 cases
To retrospectively review the radiological and clinicopathological features of gliosarcoma (GSM) and differentiate it from glioblastoma multiforme (GBM).
The clinicopathological data and imaging findings (including VASARI analysis) of 48 surgically and pathologically confirmed GSM patients (group 1) were reviewed in detail, and were compared with that of other glioblastoma (GBM) cases in our hospital (group 2).
There were 28 men and 20 women GSM patients with a median age of 52.5 years (range, 24-80 years) in this study. Haemorrhage (n = 21), a salt-and-pepper sign on T2-weighted images (n = 36), unevenly thickened wall (n = 36) even appearing as a paliform pattern (n = 32), an intra-tumoural large feeding artery (n = 32) and an eccentric cystic portion (ECP) (n = 19) were more commonly observed in the GSM group than in GBM patients. Based on our experience, GSM can be divided into four subtypes according to magnetic resonance imaging (MRI) features. When compared to GBM (group 2), there were more patients designated with type III lesions (having very unevenly thickened walls) and IV (solid) lesions among the GSM cases (group 1). On univariate prognostic analysis, adjuvant therapy (radiotherapy, chemotherapy, and radiochemotherapy) and existence of an eccentric cyst region were prognostic factors. However, Cox's regression model showed only adjuvant therapy as a prognostic factor for GSM.
When compared to GBM, certain imaging features are more likely to occur in GSM, which may help raise the possibility of this disease. All GSM patients are recommended to receive adjuvant therapy to achieve a better prognosis with radiotherapy, chemotherapy or radiochemotherapy all as options.
• Diagnosis of gliosarcoma can be suggested preoperatively by imaging.
• Gliosarcoma can be divided into four subtypes based on MRI.
• Paliform pattern and ECP tend to present in gliosarcoma more than GBM.
• The cystic subtype of gliosarcoma may predict a more dismal prognosis.
• All gliosarcoma patients should receive adjuvant therapy to achieve better prognosis.
KeywordsGliosarcoma Glioblastoma Magnetic resonance imaging Multidetector computed tomography Prognosis
Eccentric cystic portion
Propensity score matching
Visually accessible rembrandt images
Dr. Xiaoping Yi is right now a Postdoctoral Fellow in Postdoctoral Research Workstation of Pathology and Pathophysiology, Basic Medical Sciences, Xiangya Hospital, Central South University (No. 185705). We thank all the members of Department of Radiology and Professor Li’s Lab, Xiangya Hospital, for helpful discussion.
This study has received funding by the National Natural Science Foundation of China (No. 81472594, 81770781)
Compliance with ethical standards
The scientific guarantor of this publication is Professor Xuejun Li.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Written informed consent was waived by the Institutional Review Board.
Institutional Review Board approval was obtained.
• case-control study
• performed at one institution
- 1.Buckner JC, Ballman KV, Michalak JC et al (2006) Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24:3871–3879CrossRefGoogle Scholar
- 3.Han SJ, Yang I, Tihan T, Prados MD, Parsa AT (2010) Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol 96:313–320Google Scholar
- 4.Walker GV, Gilbert MR, Prabhu SS, Brown PD, McAleer MF (2013) Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. J Neurooncol 112:83–89Google Scholar
- 5.Frandsen J, Orton A, Jensen R et al (2017) Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg 21:1–6Google Scholar
- 13.Chang K, Bai HX, Zhou H et al (2017) Residual convolutional neural network for determination of IDH status in low- and high-grade gliomas from MR imaging. Clin Cancer Res 2018, 24(5):1073-1081.Google Scholar
- 22.NCBI/NCI/The Cancer Imaging Archive (TCIA) (2016), VASARI (Visually AcceSAble Rembrandt Images) MRI feature set, NCBI/NCI, Bethesda MD. Available via https://wikicancerimagingarchivenet/display/Public/VASARI+Research+Project. Accessed 25 July 2016